Status:
UNKNOWN
Nicotinamide Mononucleotide in Hypertensive Patients
Lead Sponsor:
First Affiliated Hospital, Sun Yat-Sen University
Conditions:
Hypertension
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Cardiovascular and cerebrovascular diseases are most terrible killers endangering the health of Chinese residents, and hypertension is the most important risk factor. Hypertension related vascular fun...
Eligibility Criteria
Inclusion
- Mild essential hypertensive patients (BP ranged from 130/80 to 159/99 mmHg).
- Ability to undergo Study procedures.
- Willingness/ability to provide informed consent.
Exclusion
- Participants with secondary hypertension.
- Participants suffering from diabetes mellitus, coronary heart disease, peripheral vascular disease, acute or chronic liver disease, renal insufficiency, malignancies, infectious disease, or using non-steroidal anti-inflammatory drugs, steriods, vasoactive agents.
- Known allergies to niacin or nicotinamide.
- Receiving certain concurrent supplements.
- Women who are currently pregnant or who wish to become pregnant over the course of the study follow-up or who are at suckling period.
- Unwillingness/inability to provide informed consent.
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04903210
Start Date
June 1 2021
End Date
July 31 2022
Last Update
February 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
First Affiliated Hospital,Sun Yat-sen University
Guangzhou, Guangdong, China, 510000